TearCare (TC) treatment significantly improves both clinical outcomes and functional vision in patients with dry eye disease (DED) and meibomian gland dysfunction (MGD), leading to enhanced quality of life and reading ability after just one session, according to a study.
The single-center, prospective study included 32 adults with MGD and DED, characterized by a tear break-up time (TBUT) of <10 seconds. Participants had at least 20/40 vision and had not undergone surgery or received new DED treatments in the 60 days prior to enrollment.
After treatment, 52% of participants showed a clinically significant improvement in reading speed, with >10 words-per-minute increases on the International Reading Speed Texts (IReST) test. Both IReST and Minnesota Low Vision Reading Test results reached statistical significance (P = 0.012 and P = 0.028, respectively). In addition, the Ocular Surface Disease Index (OSDI) scores decreased, and Visual Function Questionnaire-25 scores improved significantly (P < 0.001). All clinical parameters, including meibomian gland secretion scoresand TBUT, also showed marked improvement (P < 0.001).
Reference
Feng Y, Venkateswaran N, Steele A, et al. Impact of TearCare on Reading Speed in Patients with Dry Eye Disease. Clin Ophthalmol. 2024;18:2873-2878. doi: 10.2147/OPTH.S469300. PMID: 39403710; PMCID: PMC11472766.
Related Content
